Answers are grounded in this paper and cite their sources.
OBJECTIVES: To evaluate the clinical and economic impact of a structured breast cancer early detection initiative incorporating active recall and nurse navigation within a private healthcare cooperative in Brazil's supplemental health sector. METHODS: A 2-year initiative was implemented across a cooperative serving 140 000 beneficiaries. Active recall and nurse navigation were combined to improve screening adherence. Real-world administrative claims data captured direct medical costs across the continuum of care. A Markov state-transition model compared costs and outcomes between the early detection scenario and a metastatic counterfactual. A complementary cost-only analysis expressed outcomes in monetary terms. RESULTS: Over 2 years, 1999 mammograms increased screening coverage from 52% to 66%, generating appropriate downstream procedures and identifying 2 breast cancer cases. Total expenditures for screening and early-stage treatment reached R$702 485.00. The HER2-positive case identified was estimated to have incurred R$1 653 704.00 in metastatic treatment costs without early detection. Avoided expenditures resulted in net savings of R$951 219.00 and a 135% return on investment. The early detection strategy demonstrated economic dominance, with lower costs and greater expected health benefit. CONCLUSIONS: A coordinated model combining active recall and nurse navigation demonstrated feasibility, scalability, and meaningful clinical and economic value in a fragmented care environment. Early detection represents a strategically dominant intervention for improving oncological outcomes and enhancing financial sustainability in Brazil's supplemental health sector and similar hybrid systems.
No takes yet. Share an insight, caveat, or question.
Franco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: